A study published today in the journal MC Complementary Medicine and Therapies by researchers at the University of Phayao has found that cannabidiol (CBD) may help combat one of the world’s most dangerous hospital pathogens: extensively drug-resistant (XDR) Acinetobacter baumannii.
The bacterium, which is responsible for life-threatening infections in intensive care units, has been classified by the World Health Organization as a “critical-priority pathogen” due to its resistance to nearly all available antibiotics, including carbapenems and colistin. The study notes that infections caused by this bacteria are associated with a 44% mortality rate, particularly among critically ill patients.
Researchers tested 26 isolates of A. baumannii collected from ICU medical devices, many of which were multidrug-resistant or extensively drug-resistant. Two strains were resistant to all 13 antibiotics tested, including those considered last-resort options. CBD alone displayed antibacterial activity, with minimum inhibitory concentrations ranging from 3.9 µg/mL to more than 500 µg/mL. While not universally effective on its own, CBD’s impact was striking when combined with traditional antibiotics.
The strongest results came from testing CBD alongside gentamicin, meropenem, and colistin. According to the findings, the combination of CBD with gentamicin led to “a dramatic 1006.45-fold reduction in the required antibiotic concentration (from 312.5 to 0.31 µg/mL).” When paired with colistin, CBD reduced the needed dose more than 780-fold, while with meropenem it cut the dose nearly 500-fold. This synergy restored the effectiveness of antibiotics that had otherwise failed against resistant strains.
CBD also showed the ability to reduce and even eradicate biofilms, protective bacterial communities that form on surfaces such as catheters and ventilators. These biofilms are a major factor in antibiotic resistance and persistent infections. The study found that combining CBD with antibiotics reduced biofilm biomass by more than 80%, with meropenem plus CBD lowering biomass to just 13.1% of untreated controls. The authors wrote that this combination approach highlights CBD’s potential “to enhance antibiotic efficacy and combat biofilm-associated resistance in XDR A. baumannii.”
In addition to biofilm suppression, CBD exhibited rapid, concentration-dependent bactericidal activity. At four times the minimum inhibitory concentration, complete bacterial eradication occurred within two hours, while the highest tested dose eliminated the pathogen in just one hour. Even at lower concentrations, when used with antibiotics such as colistin or meropenem, CBD achieved similar results. The researchers described the effect as “rapid, concentration-dependent killing, with complete bacterial clearance at 4× MIC within 2 h.”
Further testing revealed that CBD works by damaging the bacterial membrane. Treated cells showed DNA and protein leakage, increased uptake of fluorescent dyes that signal compromised permeability, and visible structural collapse under scanning electron microscopy. Untreated cells displayed smooth, intact surfaces, while those exposed to CBD were wrinkled, ruptured, and structurally collapsed. The study concluded that “CBD disrupts bacterial membrane integrity and function, contributing to its potent antibacterial activity against XDR A. baumannii.”
CBD’s potential side effects were also examined. In human embryonic kidney (HEK293) cells, CBD was found to be moderately cytotoxic at higher concentrations, with an IC₅₀ value of 11.8 to 17.1 µg/mL depending on exposure time. At lower doses, however, the effects were limited, suggesting that combination therapy with reduced concentrations could offer both safety and effectiveness.
The authors argue that CBD represents a promising adjunct to conventional antibiotics, especially against pathogens that are otherwise untreatable. They point to potential uses in combination therapies for patients as well as in coatings for medical devices to prevent bacterial adhesion and biofilm development. At the same time, they stress that more research is needed to confirm the findings in clinical settings and to evaluate dosing, delivery, and pharmacokinetics.
“This study demonstrates that CBD exhibits potent antibacterial and anti-biofilm properties against XDR A. baumannii, particularly when used in combination with conventional antibiotics,” the researchers concluded. They add that its ability to disrupt bacterial membranes represents a key mechanism in overcoming drug tolerance and provides “a strong foundation for further investigation of CBD as a novel therapeutic strategy to combat antimicrobial resistance in clinical settings.”
More articles from The Marijuana Herald:
